XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B

cafead

Administrator
Staff member
  • cafead   Dec 08, 2019 at 12:02: AM
via XBiotech (NASDAQ:XBIT) inks an agreement with Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech for global rights to anti-inflammatory candidate bermekimab.

article source
 

<